Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy

2019111 citationsJournal Articlegold Open Access

Authors

Karin M. Knudson · National Institutes of Health

Kristin C. Hicks · National Institutes of Health

Jeffrey Schlom · National Institutes of Health

Sofia R. Gameiro · National Institutes of Health

Abstract

We provide novel insight into the mechanism of action of N-803 plus anti-PD-L1 combination and offer preclinical proof of concept supporting clinical use of N-803 in combination with checkpoint inhibitors, including for patients non- and/or minimally responsive to either monotherapy.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Immune Cell Function and Interaction Immunotherapy and Immune Responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal for ImmunoTherapy of Cancer

Volume 7, Issue 1, pp. 82-82

DOI: 10.1186/s40425-019-0551-y

Field-Weighted Citation Impact: 5.85